riluzole has been researched along with Nervous System Diseases in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Nervous System Diseases: Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate." | 6.44 | Riluzole in the treatment of mood and anxiety disorders. ( Banasr, M; Bloch, M; Coric, V; Krystal, JH; Pittenger, C; Sanacora, G, 2008) |
| "In recent years several new treatments have been introduced in neurology, sumatriptan in migraine, riluzole in amyotrophic lateral sclerosis, interferon-beta in multiple sclerosis and rivastigmine in Alzheimer's disease." | 4.80 | [New therapies in neurology, but who benefits?]. ( de Haan, RJ; Vermeulen, M, 1999) |
| "Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate." | 2.44 | Riluzole in the treatment of mood and anxiety disorders. ( Banasr, M; Bloch, M; Coric, V; Krystal, JH; Pittenger, C; Sanacora, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pittenger, C | 1 |
| Coric, V | 1 |
| Banasr, M | 1 |
| Bloch, M | 1 |
| Krystal, JH | 1 |
| Sanacora, G | 1 |
| Danesh-Meyer, HV | 1 |
| Levin, LA | 1 |
| Moha ou Maati, H | 1 |
| Peyronnet, R | 1 |
| Devader, C | 1 |
| Veyssiere, J | 1 |
| Labbal, F | 1 |
| Gandin, C | 1 |
| Mazella, J | 1 |
| Heurteaux, C | 1 |
| Borsotto, M | 1 |
| Vermeulen, M | 1 |
| de Haan, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder[NCT03017508] | Phase 2/Phase 3 | 22 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Measure Description: In the Visual Analogue Scale (VAS) participants are presented with a straight horizontal line of 100 mm in length and asked to mark the placement that would best describe the intensity of the anxiety felt at that moment. The left end (0mm) represents no anxiety and the right end (100mm) represents the worst anxiety ever felt by the participant.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks, generating a numerical score along a continuum" (NCT03017508)
Timeframe: up to 60 minutes
| Intervention | millimeters (units on a scale) (Mean) |
|---|---|
| BHV-0223 (Sublingual Riluzole) | 54.3 |
| Placebo | 62.6 |
3 reviews available for riluzole and Nervous System Diseases
| Article | Year |
|---|---|
Riluzole in the treatment of mood and anxiety disorders.
Topics: Animals; Anxiety Disorders; Excitatory Amino Acid Antagonists; Humans; Models, Biological; Mood Diso | 2008 |
Neuroprotection: extrapolating from neurologic diseases to the eye.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Endpoint Determination; Excitatory Amino | 2009 |
[New therapies in neurology, but who benefits?].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiviral Agents; Carbamates; Humans; Interferon-b | 1999 |
1 other study available for riluzole and Nervous System Diseases
| Article | Year |
|---|---|
A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases.
Topics: Cell Hypoxia; Drug Discovery; Drug Evaluation, Preclinical; Fatty Acids, Unsaturated; Fluoxetine; Gr | 2011 |